
Natera, Inc.
NTRANASDAQHealthcareMedical - Diagnostics & Research
前收盤價
US$332.03
+US$7.19 · +2.21%
NTRA公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Hold
Wait — insufficient conviction to act
估值
65
Undervalued
動能
69
Gaining
情緒
47
Mixed
風險韌性
57
Elevated Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
- 產業
- Medical - Diagnostics & Research
- 部門
- Healthcare
- 總部
- US
- 執行長
- Steven Leonard Chapman
- 上市以來
- 2015年7月1日
- 僱員
- 6,138
市場位置
日內區間
目前US$332.03,
52週區間
目前US$332.03,
- 開盤價
- US$321.61
- 前收盤價
- US$324.84
- 成交量
- 121.51萬
- 0.82× 平均值
- 平均成交量
- 147.97萬
- 日均成交量
- 市值
- 475.52億 USD
- 貝塔
- 1.51
- 市場參考 1
- 50天平均值
- US$272.65
- 高於平均水平+21.78%
- 200天平均值
- US$229.33
- 高於平均水平+44.78%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 304.6億 USD
- 本益比(TTM)
- -244.14×
- 股價淨值比(TTM)
- 26.12×
- 股價營收比(TTM)
- 17.57×
- EV/EBITDA
- -138.12×
- 盈餘收益率
- -0.66%
- 自由現金流收益率
- 0.35%
- 股息率
- 0.00%
獲利能力和效率
- 毛利率
- 65.30%
- 營業利益率
- -10.70%
- 淨利潤率
- -7.11%
- 股東權益報酬率
- -12.16%
- 資產報酬率
- -8.30%
- 投入資本報酬率
- -11.13%
財務健康
- 負債權益比
- 0.13×
- 流動比率
- 3.39×
- 奧特曼 Z 分數
- 33.8
- 皮奧特羅斯基 F 分數
- 3 共 9 個
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 23.06億 USD | 16.97億 USD | 10.83億 USD | 8.2億 USD | 6.25億 USD |
| 銷貨成本 | 8.11億 USD | 6.74億 USD | 5.9億 USD | 4.56億 USD | 3.18億 USD |
| 毛利 | 14.95億 USD | 10.23億 USD | 4.93億 USD | 3.64億 USD | 3.07億 USD |
| 研究與開發 | 6.24億 USD | 4.04億 USD | 3.21億 USD | 3.16億 USD | 2.64億 USD |
| 銷售、一般及管理費用 | 11.77億 USD | 8.41億 USD | 6.18億 USD | 5.89億 USD | 5.11億 USD |
| 營業費用 | 18.05億 USD | 12.45億 USD | 9.39億 USD | 9.05億 USD | 7.75億 USD |
| 利息收入 | 4589.1萬 USD | 4324.8萬 USD | 2435.3萬 USD | 353.8萬 USD | 538.1萬 USD |
| 利息支出 | 406.9萬 USD | 1068.5萬 USD | 1263.8萬 USD | 931.9萬 USD | 830.5萬 USD |
| 折舊和攤銷 | 4348.4萬 USD | 3096.8萬 USD | 3861.6萬 USD | 3047.2萬 USD | 1125.4萬 USD |
| 營業利益 | −3.1億 USD | −2.22億 USD | −4.46億 USD | −5.41億 USD | −4.68億 USD |
| 淨利 | −2.08億 USD | −1.9億 USD | −4.35億 USD | −5.48億 USD | −4.72億 USD |
公司資料更新於 2026年8月24日。
財報歷史與展望
- EPS優於預期率
- 64%
- 優於預期7次、低於預期4次、符合預期0次
- 平均EPS意外幅度
- +22.04%
- 11 類似報告
- 最新每股收益結果
- -0.47
- 預估-0.49 · 優於預期4.85%
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
NTRA 訊息
NTRA同業公司
持有NTRA的ETF
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI11.6億0.05%2.3兆 USD0.03%US$378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB8.37億0.45%1834億 USD0.03%US$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK4.84億1.08%438億 USD0.05%US$358.65+0.70%
Vanguard Extended Market ETFVXF4.42億0.46%937億 USD0.05%US$245.53+0.82%
iShares Biotechnology ETFIBB3.32億3.13%107.45億 USD0.44%US$213.56+1.29%
iShares Russell Mid-Cap Growth ETFIWP2.56億1.25%206.2億 USD0.23%US$143.66+0.99%
iShares Russell Mid-Cap ETFIWR1.81億0.32%576.61億 USD0.18%US$113.44+0.70%
iShares Russell 1000 Growth ETFIWF1.67億0.13%1254.68億 USD0.18%US$122.39+0.47%
Vanguard Morningstar Total Stock Market ETFVTI- 市場價值
- 11.6億
- 重量
- 0.05%
- AUM
- 2.3兆 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB- 市場價值
- 8.37億
- 重量
- 0.45%
- AUM
- 1834億 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK- 市場價值
- 4.84億
- 重量
- 1.08%
- AUM
- 438億 USD
- 費用率
- 0.05%
- 價格 / 1日
- US$358.65+0.70%
Vanguard Extended Market ETFVXF- 市場價值
- 4.42億
- 重量
- 0.46%
- AUM
- 937億 USD
- 費用率
- 0.05%
- 價格 / 1日
- US$245.53+0.82%
iShares Biotechnology ETFIBB- 市場價值
- 3.32億
- 重量
- 3.13%
- AUM
- 107.45億 USD
- 費用率
- 0.44%
- 價格 / 1日
- US$213.56+1.29%
iShares Russell Mid-Cap Growth ETFIWP- 市場價值
- 2.56億
- 重量
- 1.25%
- AUM
- 206.2億 USD
- 費用率
- 0.23%
- 價格 / 1日
- US$143.66+0.99%
iShares Russell Mid-Cap ETFIWR- 市場價值
- 1.81億
- 重量
- 0.32%
- AUM
- 576.61億 USD
- 費用率
- 0.18%
- 價格 / 1日
- US$113.44+0.70%
iShares Russell 1000 Growth ETFIWF- 市場價值
- 1.67億
- 重量
- 0.13%
- AUM
- 1254.68億 USD
- 費用率
- 0.18%
- 價格 / 1日
- US$122.39+0.47%
繼續GoAI的研究
在 GoAI 中研究NTRAresearch.disclaimer











